Glenmark Pharmaceuticals informs about update

27 Nov 2025 Evaluate

Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, Glenmark Pharmaceuticals has informed that the Company has received Establishment Inspection Report (EIR) with a Voluntary Action Indicated (VAI) status from the United States Food & Drug Administration (U.S. FDA) for its formulations manufacturing facility situated in Monroe, North Carolina, USA. This is following an inspection conducted by the Agency from 09 June to 17 June 2025. The commercial manufacturing at the Monroe site will now restart. The company had earlier informed the stock exchange (BSE) on 18 June 2025 about the Form-483 with five observations for the above June 2025 inspection. The site was earlier under Warning Letter since June 2023.

The above information is a part of company’s filings submitted to BSE.



Glenmark Pharma Share Price

1977.50 3.35 (0.17%)
05-Dec-2025 14:20 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1807.80
Dr. Reddys Lab 1275.00
Cipla 1524.60
Zydus Lifesciences 933.35
Lupin 2101.00
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×